Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology Class A Ordinary Shares (NNNN) Revenue
Annual & quarterly revenue history · segment & region breakdown
NNNN · revenue · updated Jun 10, 2026
Core revenue metrics
Trailing 12 monthsAnbio Biotechnology Class A Ordinary Shares trailing twelve-month (TTM) revenue is $0.02B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
Compare revenue vs peers
Medical - Instruments & SuppliesCompare NNNN revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Anbio Biotechnology Class A Ordinary Shares receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Anbio Biotechnology Class A Ordinary Shares reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Anbio Biotechnology Class A Ordinary Shares's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NNNN revenue · 4 questionsNNNN's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Anbio Biotechnology Class A Ordinary Shares SEC filings · GAAP · Anbio Biotechnology Class A Ordinary Shares SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026